# KLOW Peptide Results in the Research Literature | Safe KLOW > KLOW results indexed from the tissue-repair and tendon literature: thymosin beta-4 wound data, BPC-157 Achilles tendon findings, KPV colitis models, and GHK-Cu collagen studies — component-attributed, cited. Component-attributed findings from the tissue-repair and tendon canon. Every figure cited to its study. The blend-level column filed as absent. ## In plain English This page is the results register for the KLOW peptide blend's component literature, viewed through the tissue-repair and tendon lens. The results here come from animal and cell studies of the individual compounds — not from any study of the four-compound blend. There is no controlled KLOW-blend results study. Each finding below is labeled with which of the four components it belongs to. The numbers are real, the studies are cited, and the component attributions are accurate. The absence of blend-combination data is also real and is noted explicitly. Think of this as four separate evidence columns filed under one shelfmark — with the fifth column, 'blend combination results', left blank because no researcher has yet filled it. ## Tissue repair and wound healing **TB-500 arm:** In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by +42% at day 4 and up to +61% at day 7 versus saline controls. Wound contraction improved by at least 11% by day 7. Collagen deposition and angiogenesis were elevated. As little as 10 picograms stimulated keratinocyte migration two-to-three-fold in assay [1]. These data are for full-length native thymosin beta-4; the TB-500 heptapeptide fragment carries the actin-sequestering LKKTET motif but the full suite of native-protein activities has not been demonstrated for the fragment [12]. **BPC-157 arm:** Intraperitoneal BPC-157 (10 mcg, 10 ng, or 10 pg/rat, once daily) accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic, and macroscopic measures, and stimulated tendocyte outgrowth in vitro [2]. BPC-157 also improved recovery from crush injury to the gastrocnemius muscle [9] and rescued corticosteroid-impaired muscle healing [8], and improved healing of a segmental bone defect in a rabbit model [10]. **GHK-Cu arm:** Topical GHK-Cu increased collagen production in 70% of treated women vs. 50% for vitamin C and 40% for retinoic acid in a placebo-controlled comparison; GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate, and the proteoglycan decorin [4]. GHK modulates approximately 31.2% of human genes at a 50%-or-greater change threshold, with strongest effects on extracellular-matrix, antioxidant, and DNA-repair gene sets [5]. **KPV arm:** Nanomolar KPV inhibited NF-kappaB and MAPK signaling and reduced pro-inflammatory cytokine secretion in human intestinal epithelial and immune cells; oral KPV at 100 micromolar in drinking water reduced colitis severity in DSS- and TNBS-induced mouse models [3]. **Blend-level results:** No controlled study has tested the four-peptide KLOW combination. This column is blank — NONE ON RECORD. ## Recent studies and the evolving record A 2026 case study in Pharmaceuticals (Basel) documented resolution of a tracheocutaneous fistula (an abnormal channel between windpipe and skin) following BPC-157 administration, linked mechanistically to its nitric-oxide system modulation [14]. This is a single case report and is not a controlled efficacy demonstration. A 2026 Sports Medicine systematic review by Mendias and Awan evaluated both approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, listing TB-500/thymosin beta-4 and BPC-157 specifically [7]. The review concluded that animal-model outcomes are favorable for tissue repair but that rigorous human safety data are scarce. The authors noted that these compounds operate largely outside regulatory oversight and carry potential for serious harm without clinical validation. A 2025 IV BPC-157 safety pilot — the first-in-human intravenous administration of BPC-157 — reported no adverse events in two adults receiving 10 mg on day 1 and 20 mg on day 2 [6]. This is an open-label, two-subject, non-efficacy pilot, not a Phase I clinical trial. ## What the klow results record does and does not establish The [KLOW research](/research) establishes the following for the individual components, within the constraints of their study models: - TB-500/thymosin beta-4: measurable wound-healing improvements in rat models, with active doses as small as 10 picograms in keratinocyte migration assays. - BPC-157: accelerated tendon, muscle, and bone healing across multiple rodent models, with an early human safety signal from a 2-person IV pilot. - KPV: PepT1-mediated uptake into inflamed intestinal epithelium and NF-kappaB suppression in cell culture, with oral efficacy in mouse colitis models. - GHK-Cu: collagen and matrix synthesis stimulation in clinical topical studies, broad transcriptomic modulation in fibroblast cultures. What the record does not establish: any combined efficacy, safety, or pharmacokinetic profile for the four-peptide co-formulation. The blend-level results column is empty. The honest gap is catalogued as that — an absent record, not a negative result. --- A catalogued index of the four-constituent literature — what each component's studies measured, the blend's combination column filed as the ruled blank it is.